Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: Results of an international first-in-class phase II study

Annals of Oncology

Volumn 25, Issue 6, 2014, Pages 1152-1158

  Delaloge, Suzette ^a   Wolp Diniz, R ^a   Byrski, T ^b   Blum, J L ^c   Goncalves A ^d   Campone, M ^e   Lardelli, P ^f   Kahatt, C ^f   Nieto, A ^f   Cullell Young, M ^f   Lubinski, J ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b International Hereditary Cancer Center   (Poland)

^c TEXAS ONCOLOGY   (United States)

^d INSTITUT PAOLI CALMETTES   (France)

^e Institut de Cancérologie de l'OUEST ^*  (France)

^f PHARMAMAR S A   (Spain)

Author keywords

BRCA1 2; Breast cancer; Chemotherapy; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; TRABECTEDIN; TUMOR MARKER; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRCA2 GENE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GENE; GENE MUTATION; GERMLINE MUTATION; HEMATOLOGIC DISEASE; HETEROZYGOTE; HUMAN; INTERNATIONAL COOPERATION; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BREAST NEOPLASMS; DIOXOLES; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; TETRAHYDROISOQUINOLINES;

EID: 84903900546     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu134     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
4. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat 2010; 119: 13-24.
5. Graeser MK, Engel C, Rhiem K et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009; 27: 5887-5892.
6. Pierce LJ, Levin AM, Rebbeck TR et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006; 24: 2437-2443.
7. Metcalfe KA, Lynch HT, Ghadirian P et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 2005; 96: 222-226.
8. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7: 961-966.
9. Soares DG, Escargueil AE, Poindessous V et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007; 104: 13062-13067.
10. Casado JA, Rio P, Marco E et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008; 7: 1309-1318.
11. D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9: 2157-2163.
12. Schoffski P, Taron M, Jimeno J et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011; 47: 1006-1012.
13. Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009; 45: 1153-1161.
14. Zelek L, Yovine A, Brain E et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94: 1610-1614.
15. Gurtler JS, Goldstein L, Delprete S et al. Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 2005; 23: 625. ASCO Annual Meeting Proceedings.
16. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
17. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663.
20. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291.
21. Garcia MJ, Saucedo-Cuevas LP, Munoz-Repeto I et al. Analysis of DNA repairrelated genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther 2013; 12: 530-541.
22. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
23. Tassone P, Di Martino MT, Ventura M et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009; 8: 648-653.
24. Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009; 27: 502.
25. Soares DG, Machado MS, Rocca CJ et al. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 2011; 10: 1481-1489.
26. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
27. Schoffski P, Dumez H, Wolter P et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008; 9: 1609-1618.
28. Michaelson MD, Bellmunt J, Hudes GR et al. Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2012; 23: 1234-1240.
29. Del Campo JM, Sessa C, Krasner CN et al. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 2013; 30: 435.
30. Massuti B, Cobo M, Camps C et al. Trabectedin in patients with advanced nonsmall- cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer 2012; 76: 354-361.
31. Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23: 771-776.
32. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23: 5484-5492.